Article

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France.
British Journal of Cancer (Impact Factor: 5.08). 01/2009; 99(11):1959. DOI: 10.1038/sj.bjc.6604800
Source: PubMed

ABSTRACT Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the expression of EGF-receptor, Her-2/neu, and c-Kit tyrosine kinases in CUP. Paraffin-embedded specimens were obtained from 54 patients with a CUP who were included in the GEFCAPI 01 randomised phase II trial. Immunohistochemistry was performed using the Dako autostainer with antibodies directed against HER-2/neu protein, EGFR protein, and c-Kit protein (CD117). EGFR expression was found in 36 out of 54 samples (66%). In contrast, Her-2/neu overexpression and c-Kit positivity were only detected in 4 and 10% of patients, respectively. No significant association was found between the expression of the tyrosine kinase receptors and prognosis. EGFR expression was significantly associated with response to cisplatin-based chemotherapy: the response rates were 50 and 22% in patients with EGFR-positive tumours and EGFR-negative tumours, respectively (P<0.05). This study shows that EGFR is frequently expressed in CUP. This finding may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity.

0 Bookmarks
 · 
86 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Patienten mit disseminierter Metastasierung eines CUP-Syndroms haben eine ernste Prognose mit einem medianen Überleben von 3–10 Monaten je nach Allgemeinzustand und Ausmaß der Erkrankung. Spezifisch behandelbare Subgruppen wie neuroendokrine Karzinome oder extragonadale Keimzelltumoren müssen unbedingt erkannt werden, da sie bei sachgerechter Therapie eine wesentlich günstigere Prognose haben. Ansonsten sollte versucht werden, aufgrund des Musters der Metastasierung und der Immunhistologie eine Arbeitsdiagnose zu finden, um ein Chemotherapieregime zu wählen. Für das CUP-Syndrom ohne Arbeitsdiagnose ist die Kombination von Carboplatin und Paclitaxel das Standardschema, welches zu objektiven Remissionraten von etwa 20–40% und zu medianen Überlebenszeiten von 10–12 Monaten führt. Sequenzielle Chemotherapieregime oder gezielte Therapien wie monoklonale Antikörper und Tyrosinkinasehemmer erwiesen sich bisher nicht als klar überlegen und werden aktuell im Rahmen von Studien geprüft.
    Der Onkologe 01/2008; 14(9):920-930. · 0.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are few existing reports on the efficacy of second-line chemotherapy in patients with cancer of unknown primary site (CUP). The aim of this study was to identify characteristics of CUP patients linked to a positive response to chemotherapy. We retrospectively studied the clinical outcomes of second-line chemotherapy in patients with CUP who had previously been treated with platinum-based first-line chemotherapy. A total of 27 patients received second-line chemotherapy. Of these patients, 5 (19%) showed an objective response to second-line chemotherapy; 4 of these patients had shown a favorable response to first-line chemotherapy and had a chemotherapy-free interval (CFI) of more than 4.5 months. Among the 8 patients in whom the CFI was more than 4.5 months, 4 (50%) showed an objective response to platinum-based second-line chemotherapy, whereas among the 16 patients with a CFI of less than 4.5 months, only 1 (6%) showed a response to any chemotherapeutic regimen. The response to second-line chemotherapy in CUP patients who had received platinum-based first-line treatment seemed to be associated with the response to first-line chemotherapy and the CFI. Although it remains unclear whether second-line chemotherapy might contribute to a survival benefit in patients with CUP, patients who show a favorable response to first-line chemotherapy and also a relatively prolonged CFI appear to be likely to benefit from second-line chemotherapy.
    Journal of Cancer Research and Clinical Oncology 05/2011; 137(8):1185-91. · 2.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most nonlinear dynamics and chaos literature is written either for readers of popular science magazines or for advanced mathematicians. This paper gives a broad introduction to this interesting and rapidly growing field at a level that is between the two. The graphical and analytical tools used in the literature are explained, a brief outline of the current theory is given, and that theory is illustrated with several examples: an electronic circuit, a chemical reaction and a system of satellites in the solar system.
    Computers & Graphics 01/1995; · 0.79 Impact Factor

Full-text (2 Sources)

View
2 Downloads
Available from
Sep 15, 2014